Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer patients get continued access to key therapy in extension study

NCT ID NCT05112965

Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment available while monitoring for serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

49 people

The number who actually took part.

Started

Dec 2021

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Eligible for continuing or crossing over to atezolizumab-based therapy at the time of rollover from the parent study, as per the parent study protocol, or * Eligible for continuing the comparator agent(s) in a Genentech- or Roche-sponsored study as per the parent study protocol, with no access to commercially available comparator agent * First dose of study treatment in this extension study will be received within 7 days of the treatment interruption window allowed by the parent study * Continue to benefit from atezolizumab-based study treatment or from the comparator at the time of rollover from the parent study as assessed by the investigator * Negative serum pregnancy test within 7 days prior to start of study treatment in women of childbearing potential * For women of childbearing potential: agreement to remain abstinent or use contraceptive methods, and agreement to refrain from donating eggs * For men: agreement to remain abstinent or use contraceptive measures, and agreement to refrain from donating sperm Exclusion Criteria: * Meet any of the study treatment discontinuation criteria specified in the parent study at the time of enrollment in the extension study * Study treatment is commercially marketed in the patient's country for the patient-specific disease and is accessible to the patient * Time between the last dose of treatment received in parent study and first dose in extension study is longer than the interruption period (±7 days) allowed in the parent study * Treatment with any anti-cancer treatment (other than treatment permitted in the parent study) during the time between last treatment in the parent study and the first dose of study treatment in the extension study * Permanent discontinuation of atezolizumab for any reason during the parent study or during the time between last treatment in the parent study and the first dose of study treatment in the extension study (if applicable) * Any unresolved or irreversible toxicities during the parent study that required permanent discontinuation of study treatment, in accordance to the parent study or local prescribing information * Ongoing serious adverse events that have not resolved to baseline level or Grade ≤1 from the parent study or during the time between the last treatment in the parent study and the first dose of study treatment in the extension study * Any serious uncontrolled concomitant disease that would contraindicate the use of study treatment at the time of the extension study or that would place the patient at high risk for treatment-related complications * Concurrent participation in any therapeutic clinical trial (other than the parent study) * Pregnant or lactating, or intending to become pregnant during the extension study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Neoplasms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Neoplasms

Contacts and locations

Locations

  • Beijing Cancer Hospital

    Beijing, 100142, China

  • Cancer Hospital of Shandong First Medical University

    Jinan, Shandong, 250117, China

  • Changchun Cancer Hospital

    Changchun, 130000, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150081, China

  • Henan Cancer Hospital

    Zhengzhou, 450008, China

  • Hunan Cancer Hospital

    Changsha, 410013, China

  • Jiangsu Cancer Hospital

    Nanjing, 211100, China

  • Jilin Cancer Hospital

    Changchun, 132013, China

  • Nanfang Hospital, Southern Medical University

    Guangzhou, Guangdong, 510515, China

  • Peking Union Medical College Hospital

    Beijing, 100730, China

  • Shanghai Chest Hospital

    Shanghai, 200000, China

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang, 310016, China

  • The 2nd Hospital of Tianjin Medical University

    Tianjin, 300211, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, 510120, China

  • Tianjin Cancer Hospital

    Tianjin, 300060, China

  • Union Hospital of Tongji Medical College, Dept. of Cancer Center

    Wuhan, Hubei, 430022, China

  • Zhejiang Cancer Hospital

    Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.